483
Mary Kay, IncFDA 483 - Mary Kay, Inc - July 19, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Mary Kay, Inc.'s OTC drug facility in Dallas, TX, revealed three significant observations. These included failures in preventing contamination during component handling and storage, inadequate visual examination of incoming component containers for damage, and deficient procedures for equipment cleaning and maintenance. The findings indicate issues with quality control and adherence to good manufacturing practices.
- Office
- Dallas District Office
- Person
Open in Dashboard
ID · 7579fde1-a80c-4e4f-ba13-7ff2cddf7444